Q-omics provides the consensus-scored CYP21A2 profile across patient tissues and cancer cell-line models. CYP21A2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYP21A2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CYP21A2 RNA expression shows 13,562 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where CYP21A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP21A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP21A2 survival associations across molecular data types. CYP21A2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP21A2 RNA expression–survival associations across cancer types. High CYP21A2 expression shows unfavorable associations in KIRC, COAD, LUAD, STAD and ACC, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYP21A2 RNA expression.
This table summarizes CYP21A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP21A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP21A2 shows lower tumor expression in BLCA, KICH and HNSC and higher tumor expression in KIRC, THCA and BRCA. The KIRC box plot shows higher CYP21A2 RNA expression in tumor versus normal tissue (log2 FC = +0.737, t-test p < 0.001).
This table shows molecular features associated with CYP21A2 in patient tissues and cancer cell lines. In patient samples, CYP21A2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP21A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
